etanercept · Enbrel

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (5)
US
  • Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.
  • Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).
Product first approved 1998Outside this platform's coverageFDA label
CA
  • ENBREL is indicated for: • treatment of moderately to severely active rheumatoid arthritis (RA) in adults. Treatment is effective in reducing the signs and symptoms of RA, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function. ENBREL can be initiated in combination with methotrexate (MTX) in adult patients or used alone. • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years who have had an inadequate response to one or more disease-modifying...
Product first approved 2005Health Canada
EU
  • Enbrel: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis (adults and paediatric)
Product first approved 2000EMA
JP
  • Rheumatoid arthritis; Wyeth K.K. and Takeda
healthday.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (63)
Psoriasis
NCT03073200 · Eli Lilly and Company
2017-03-28 – 2021-03-23 · Plaque Psoriasis
What this study did
NCT02701205 · Shanghai Celgen Bio-Pharmaceutical Co.,Ltd
2015-01 – 2017-12 · Plaque Psoriasis, Psoriasis
What this study did
NCT00141921 · Amgen
2005-08-11 – 2017-08-16 · Pediatric Plaque Psoriasis
What this study did
NCT01313221 · Amgen
2011-04 – 2013-05 · Psoriasis
What this study did
NCT01235442 · Amgen
2010-09 – 2011-12 · Psoriasis
What this study did
NCT00482170 · Pfizer
2007-09 – 2009-09 · Psoriasis
What this study did
NCT00121615 · Amgen
started 2004-10 · Inflammation, Psoriasis
What this study did
NCT00333034 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-06 – 2007-05 · Psoriasis
What this study did
NCT00116181 · Rockefeller University
2004-10 – 2007-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT01690299 · Amgen
2012-10-01 – 2016-04-04 · Psoriasis, Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT02373813 · Amgen
2015-02-20 – 2019-12-06 · Rheumatoid Arthritis
What this study did
NCT03403140 · Gema Biotech S.A.
2016-10-06 – 2018-10-31 · Rheumatoid Arthritis
What this study did
NCT02986139 · Amgen
2016-11-29 – 2017-10-09 · Arthritis, Rheumatoid; Arthritis, Psoriatic
What this study did
NCT03332719 · Gema Biotech S.A.
2016-02 – 2017-09 · Rheumatoid Arthritis
What this study did
NCT02638259 · Sandoz
2015-02-21 – 2017-06-12 · Rheumatoid Arthritis
What this study did
NCT02378506 · Pfizer
2015-04 – 2016-06 · Arthritis, Rheumatoid
What this study did
NCT02164214 · Assistance Publique Hopitaux De Marseille
2011-09 – 2015-09 · Inflammatory Rheumatism, Psoriatic Arthritis, Rheumatoid Arthritis
What this study did
NCT01901185 · Amgen
2013-06-11 – 2013-12-30 · Rheumatoid Arthritis, Psoriatic Arthritis
What this study did
NCT00110903 · Amgen
— · Rheumatoid Arthritis
What this study did
NCT01270997 · Hanwha Chemical
2010-12 – 2012-05 · Rheumatoid Arthritis
What this study did
NCT00445770 · Pfizer
2006-07 – 2010-07 · Arthritis, Rheumatoid
What this study did
NCT00459706 · Pfizer
2007-09 – 2009-09 · Rheumatoid Arthritis
What this study did
NCT00356590 · Amgen
1998-12 – 2009-04 · Rheumatoid Arthritis
What this study did
NCT00484237 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-04 – 2007-12 · Rheumatoid Arthritis
What this study did
NCT00418717 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-02 – 2007-12 · Arthritis, Rheumatoid
What this study did
NCT00413452 · Amgen
2006-12 – 2007-10 · Rheumatoid Arthritis
What this study did
NCT00443950 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-06 – 2007-07 · Arthritis, Rheumatoid
What this study did
NCT00249041 · Amgen
2005-10 – 2007-03 · Rheumatoid Arthritis
What this study did
NCT00522184 · Centre Hospitalier Universitaire de Nice
2005-02 – 2006-11 · Rheumatoid Arthritis
What this study did
NCT00317538 · Centocor Ortho Biotech Services, L.L.C.
2003-06 – 2004-11 · Rheumatoid Arthritis
What this study did
NCT00078806 · Amgen
2001-06-04 – 2004-05-06 · Juvenile Rheumatoid Arthritis
What this study did
NCT03781375 · Amgen
2000-08-24 – 2002-06-24 · Juvenile Rheumatoid Arthritis
What this study did
NCT00393471 · Wyeth is now a wholly owned subsidiary of Pfizer
2000-10 – 2001-10 · Active Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03728478 · Istituto Giannina Gaslini
2019-05-29 – 2026-12-31 · Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative
What this study did
NCT07386587 · University of Child Health Sciences and Children's Hospital, Lahore
2026-01-27 – 2026-07-27 · Juvenile Idiopathic Arthritis
What this study did
NCT02987257 · Vanderbilt University Medical Center
2023-03-21 – 2025-10-31 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
What this study did
NCT01421069 · Pfizer
2011-10-10 – 2021-02-04 · Juvenile Idiopahtic Arthritis
What this study did
NCT02840175 · Assistance Publique - Hôpitaux de Paris
2017-05-18 – 2020-10-01 · Juvenile Idiopathic Arthritis
What this study did
NCT00468117 · National Institute of Allergy and Infectious Diseases (NIAID)
2007-01 – 2017-07-05 · Type 1 Diabetes Mellitus
What this study did
NCT04345458 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014-03-06 – 2015-07-20 · Ankylosing Spondylitis
What this study did
Phase 2/3 (10)
Psoriasis
NCT03997786 · Sun Pharmaceutical Industries Limited
2020-01-15 – 2031-08-05 · Moderate-to-severe Chronic Plaque Psoriasis
What this study did
Rheumatoid Arthritis
Other / comorbidity
NCT06011889 · National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
2024-09-04 – 2028-10-18 · SAPHO Syndrome
What this study did
NCT01030120 · University of Utah
2010-12 – 2012-10 · Chronic Idiopathic Urticaria
What this study did
NCT00789997 · Ottawa Hospital Research Institute
2008-11 – 2011-10 · COPD Exacerbation
What this study did
NCT00733096 · Johns Hopkins University
2008-08 – 2011-03 · Lumbosacral Radiculopathy
What this study did
NCT00127387 · The University of Texas Health Science Center at San Antonio
2001-05 – 2005-11 · Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
What this study did
NCT00111956 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2004-04 – 2005-05 · Metabolic Syndrome X
What this study did
NCT00005007 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2000-06 – 2003-03 · Wegener's Granulomatosis
What this study did
NCT00035958 · Children's Hospital Medical Center, Cincinnati
2002-08 – 2002-08 · Dermatomyositis
What this study did
Phase 2 (48)
Psoriasis
NCT01989689 · Emory University
2010-08 – 2013-09 · PSORIASIS
What this study did
NCT00134394 · University of Medicine and Dentistry of New Jersey
2005-02 – 2007-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT03193957 · Samsung Bioepis Co., Ltd.
2017-05-15 – 2017-09-25 · Rheumatoid Arthritis
What this study did
NCT00034060 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002-04 – 2005-12 · Rheumatoid Arthritis, Healthy
What this study did
NCT00001862 · National Eye Institute (NEI)
1999-02 – 2003-03 · Juvenile Rheumatoid Arthritis, Uveitis
What this study did
Other / comorbidity
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT04066348 · Wayne State University
2022-07-01 – 2027-02 · Tinnitus, Noise Induced
What this study did
NCT02464878 · Massachusetts General Hospital
2017-01 – 2022-12 · Kidney Transplant, Type 1 Diabetes
What this study did
NCT02464033 · Johnny Ludvigsson
2015-05 – 2019-02-25 · Diabetes Mellitus, Type 1
What this study did
NCT00841789 · Michael Portman
2009-03 – 2018-08-30 · Mucocutaneous Lymph Node Syndrome, Kawasaki Disease
What this study did
NCT02656082 · University of Leeds
2016-02-01 – 2017-12-31 · Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous
What this study did
NCT00639717 · University of Michigan Rogel Cancer Center
2009-03 – 2016-04 · Graft Versus Host Disease
What this study did
NCT01731457 · Medical University of Warsaw
2011-04 – 2016-02 · Transplanted Kidney Ischemia Reperfusion Injury
What this study did
NCT00789308 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-07-11 – 2014-08-21 · Diabetes Mellitus, Type I
What this study did
NCT01730495 · Haukeland University Hospital
2012-10 – 2014-08 · Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
What this study did
NCT01068353 · University of Southampton
2011-01 – 2013-12 · Alzheimer's Disease
What this study did
NCT00434850 · National Institute of Allergy and Infectious Diseases (NIAID)
2006-10 – 2013-11 · Diabetes Mellitus, Type 1
What this study did
NCT00844142 · Charite University, Berlin, Germany
2005-11 – 2013-07 · Moderate to Severe Active Axial Spondyloarthritis
What this study did
NCT00141739 · University of Michigan Rogel Cancer Center
2004-08 – 2012-09 · Graft-Versus-Host Disease
What this study did
NCT00224874 · National Heart, Lung, and Blood Institute (NHLBI)
2005-09 – 2012-06 · Graft vs Host Disease, Immune System Disorders
What this study did
NCT01289743 · Charite University, Berlin, Germany
2002-02 – 2012-05 · Ankylosing Spondylitis
What this study did
NCT01289730 · Charite University, Berlin, Germany
2002-02 – 2012-05 · Spondyloarthritis
What this study did
NCT00309907 · Children's Oncology Group
2006-04 – 2011-09 · Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
What this study did
NCT00797784 · Florida Academic Dermatology Centers
2008-10 – 2011-04 · Discoid Lupus Erythematosus (DLE)
What this study did
NCT00031551 · National Institute of Nursing Research (NINR)
2002-03 – 2010-08 · Stomatitis
What this study did
NCT00293202 · Kaysen, George A., M.D., Ph.D.
2005-01 – 2010-06 · End Stage Renal Disease
What this study did
NCT00285779 · Stanford University
2006-08 – 2009-11 · Lichen Planus
What this study did
NCT00509600 · M.D. Anderson Cancer Center
2004-09 – 2009-04 · Leukemia
What this study did
NCT00447265 · National Institute of Allergy and Infectious Diseases (NIAID)
2008-02 – 2009-03 · Lupus Nephritis
What this study did
NCT00141726 · University of Michigan Rogel Cancer Center
2003-10 – 2009-02 · Lung Injury, Acute, Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans
What this study did
NCT00107991 · University of Pennsylvania
2005-04 – 2008-11 · Hidradenitis Suppurativa
What this study did
NCT00134368 · University of Medicine and Dentistry of New Jersey
2003-11 – 2007-12 · Vitiligo
What this study did
NCT00678782 · University of Padova
2005-04 – 2007-12 · Persistent Knee Joint Synovitis
What this study did
NCT00217386 · Fred Hutchinson Cancer Center
2004-03 – 2007-12 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
NCT00135720 · Massachusetts General Hospital
2004-06 – 2007-11 · Pemphigus Vulgaris
What this study did
NCT00141713 · University of Michigan Rogel Cancer Center
2003-10 – 2006-12 · Graft-Versus-Host Disease
What this study did
NCT00141791 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-05 – 2006-07 · Asthma
What this study did
NCT00329823 · University of Athens
2005-09 – 2006-05 · Hidradenitis Suppurativa
What this study did
NCT00224393 · The Cleveland Clinic
2001-02 – 2005-08-31 · Primary Systemic Amyloidosis
What this study did
NCT00005853 · Fred Hutchinson Cancer Center
1999-12 – 2005-08 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00001901 · National Institute of Allergy and Infectious Diseases (NIAID)
1999-02 – 2005-03 · Vasculitis, Wegener's Granulomatosis
What this study did
NCT00063869 · Wyeth is now a wholly owned subsidiary of Pfizer
est. completion 2005-03 · Pulmonary Fibrosis
What this study did
NCT00006070 · National Institute of Dental and Craniofacial Research (NIDCR)
2000-07 – 2004-05 · Healthy, Inflammation
What this study did
NCT00048373 · Baylor College of Medicine
2001-10 – 2004-04 · Histiocytosis, Langerhans-Cell
What this study did
NCT00001955 · National Institute of Dental and Craniofacial Research (NIDCR)
1999-12 – 2004-02 · Temporomandibular Joint Disorder
What this study did
NCT00001954 · National Institute of Dental and Craniofacial Research (NIDCR)
1999-12 – 2003-11 · Sjogren's Syndrome
What this study did
NCT00001893 · National Heart, Lung, and Blood Institute (NHLBI)
1999-08-17 – 2002-12-31 · Asthma
What this study did
Phase 1/2 (13)
Psoriasis
NCT02112097 · ASIS Corporation
2016-01 – 2017-06 · Plaque Psoriasis.
What this study did
NCT00585650 · University of California, Irvine
2007-05 – 2008-05 · Psoriasis
What this study did
Other / comorbidity
NCT03182426 · University of Alberta
2017-08-15 – 2024-07-15 · Diabetes Mellitus, Type 1
What this study did
NCT02821026 · University of Alberta
2016-05 – 2019-11-13 · Type 1 Diabetes
What this study did
NCT00784966 · Virginia Commonwealth University
2011-08 – 2017-09 · Type 1 Diabetes Mellitus
What this study did
NCT00888628 · Massachusetts General Hospital
2009-05 – 2016-08 · Diabetes Mellitus, Type I
What this study did
NCT00201682 · John Byrd
2002-10 – 2009-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT00118287 · Fred Hutchinson Cancer Center
2005-04 – 2008-10 · de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
What this study did
NCT00730392 · State University of New York at Buffalo
2002-10 – 2008-01 · Type 1 Diabetes
What this study did
NCT00364572 · Johns Hopkins University
2006-05 – 2007-12 · Sciatica
What this study did
NCT00201838 · Ohio State University Comprehensive Cancer Center
2001-07 – 2007-05 · Pancreatic Neoplasms, Adenocarcinoma
What this study did
NCT00093366 · Fred Hutchinson Cancer Center
2004-06 – 2006-07 · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
What this study did
NCT00029328 · FDA Office of Orphan Products Development
2001-09 – 2003-09 · Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
What this study did
Phase 1 (32)
Psoriasis
NCT02999776 · Pantec Biosolutions AG
2016-11 – 2018-06 · Psoriatic Plaque
What this study did
Rheumatoid Arthritis
NCT04585711 · Duke University
2026-07-01 – 2027-02-28 · Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity
What this study did
NCT04559412 · Sorrento Therapeutics, Inc.
2021-03-15 – 2024-12 · Rheumatoid Arthritis
What this study did
NCT01294397 · Amgen
2011-03 – 2016-01 · Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
What this study did
NCT00361634 · Amgen
2006-09 – 2010-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03294954 · Baylor College of Medicine
2018-01-18 – 2040-08-10 · Neuroblastoma
What this study did
NCT06585384 · Fondation Ophtalmologique Adolphe de Rothschild
2025-04-15 – 2028-12 · Alzheimer Disease
What this study did
NCT05950724 · Northwestern University
2023-09-17 – 2027-12 · Lung Transplant; Complications
What this study did
NCT04254627 · Nova Southeastern University
2021-09-24 – 2025-09-30 · Gulf War Illness
What this study did
NCT05281614 · Benaroya Research Institute
2022-09-21 – 2024-01-10 · Type 1 Diabetes
What this study did
NCT03792841 · Amgen
2019-02-05 – 2023-06-29 · Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
What this study did
NCT04973566 · Janssen Research & Development, LLC
2021-08-31 – 2022-05-27 · Healthy
What this study did
NCT01865630 · Unity Health Toronto
2021-01 – 2022-01 · Subarachnoid Hemorrhage, Aneurysmal
What this study did
NCT04255498 · South Florida Veterans Affairs Foundation for Research and Education
2017-10-30 – 2020-08-30 · Gulf War Illness, Persian Gulf Syndrome, Occupational Diseases
What this study did
NCT03193203 · Samsung Bioepis Co., Ltd.
2017-03-24 – 2017-08-07 · Healthy
What this study did
NCT03273088 · AryoGen Pharmed Co.
2016-12-04 – 2017-03-15 · Phase 1, Bioequivalence
What this study did
NCT01716637 · Life Extension Foundation Inc.
2010-02 – 2016-05 · Alzheimer's Disease
What this study did
NCT01894412 · Hanwha Chemical
2013-07 – 2015-12 · Healthy
What this study did
NCT00802815 · Washington University School of Medicine
2005-04 – 2014-05 · Inclusion Body Myositis
What this study did
NCT01725620 · LG Life Sciences
2012-11 – 2014-04 · Healthy
What this study did
NCT01865552 · Samsung Bioepis Co., Ltd.
2013-05 – 2013-08 · Healthy
What this study did
NCT01145950 · LG Life Sciences
2010-06 – 2011-01 · Healthy
What this study did
NCT00965666 · Children's Hospital Medical Center, Cincinnati
2005-10 – 2010-10 · Fanconi Anemia
What this study did
NCT00112385 · Brigham and Women's Hospital
2006-03 – 2010-06 · Dermatomyositis
What this study did
NCT00705042 · Wyeth is now a wholly owned subsidiary of Pfizer
2008-07 – 2008-11 · Healthy Subjects
What this study did
NCT00502879 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-07 – 2007-08 · Healthy
What this study did
NCT00203359 · Tobinick, Edward Lewis, M.D.
2004-09 – 2006-04 · Alzheimer's Disease
What this study did
NCT00203320 · Tobinick, Edward Lewis, M.D.
2005-04 – 2006-01 · Alzheimer's Disease
What this study did
NCT00201812 · Ohio State University Comprehensive Cancer Center
2000-11 – 2005-05 · Tumors
What this study did
NCT00091741 · Georgetown University
est. completion 2004-10 · HIV Infection
What this study did
NCT02799498 · Amgen
2003-10 – 2004-01 · Healthy Men and Women
What this study did
Phase 4 (102)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT02313922 · Zhejiang University
2014-11 – 2018-08 · Psoriasis
What this study did
NCT02749370 · Amgen
2016-05-18 – 2017-12-06 · Plaque Psoriasis
What this study did
NCT01971346 · University of Michigan
2014-03-13 – 2017-11-01 · Psoriasis
What this study did
NCT02274792 · Amgen
2015-01 – 2015-11 · Plaque Psoriasis
What this study did
NCT01543204 · Amgen
2012-02-01 – 2015-05-29 · Psoriasis
What this study did
NCT00967538 · Innovaderm Research Inc.
2009-09 – 2014-07 · Psoriasis
What this study did
NCT00992394 · Pfizer
2010-01 – 2013-04 · Psoriasis
What this study did
NCT01053819 · University of Alabama at Birmingham
2007-09 – 2012-04 · Psoriasis, Melanoma, Non-melanoma Skin Cancer
What this study did
NCT01132235 · Florida Academic Dermatology Centers
2010-04 – 2010-12 · Psoriasis
What this study did
NCT01237262 · University of Padova
2010-11 – 2010-11 · Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.
What this study did
NCT00640393 · Innovaderm Research Inc.
2008-04 – 2010-03 · Psoriasis Vulgaris
What this study did
NCT00791765 · Amgen
2008-10 – 2010-03 · Psoriasis
What this study did
NCT00332332 · Amgen
2006-03 – 2010-02 · Psoriasis
What this study did
NCT00833729 · Dermatrials Research
2009-02 – 2010-02 · Plaque Psoriasis
What this study did
NCT00663052 · Pfizer
2008-06 – 2010-01 · Plaque Psoriasis, Psoriasis
What this study did
NCT00581555 · Pfizer
2007-10 – 2009-11 · Psoriasis
What this study did
NCT00581100 · Wyeth is now a wholly owned subsidiary of Pfizer
2007-09 – 2009-10 · Nail Psoriasis, Plaque Psoriasis
What this study did
NCT00581165 · Wyeth is now a wholly owned subsidiary of Pfizer
2006-02 – 2007-08 · Psoriasis
What this study did
NCT00195507 · Wyeth is now a wholly owned subsidiary of Pfizer
2004-12 – 2007-02 · Psoriasis
What this study did
NCT00110981 · Amgen
2005-03 – 2006-03 · Psoriasis
What this study did
Psoriatic Arthritis
NCT05135312 · OptiSkin Medical
2021-08-09 – 2022-08-08 · Psoriasis, Psoriatic Arthritis, Psoriatic Nail
What this study did
NCT00111124 · Amgen
— · Psoriasis
What this study did
NCT00127842 · Amgen
2005-08 – 2009-09 · Psoriatic Arthritis
What this study did
NCT00432406 · Chinese University of Hong Kong
2006-05 – 2009-03 · Psoriatic Arthritis
What this study did
NCT00245960 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-12-27 – 2008-03-29 · Psoriatic Arthritis
What this study did
NCT00133315 · Hvidovre University Hospital
2004-09 – 2007-04 · Spondylarthropathies, Ankylosing Spondylitis, Psoriatic Arthritis
What this study did
NCT00161655 · Wyeth is now a wholly owned subsidiary of Pfizer
2005-04 – 2006-12 · Psoriasis, Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT03976245 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2020-03-01 – 2025-03 · Rheumatoid Arthritis
What this study did
NCT01793519 · Georgetown University
2013-01 – 2024-08-30 · Rheumatoid Arthritis
What this study did
NCT03813771 · University of Leeds
2019-03 – 2023-02 · Rheumatoid Arthritis
What this study did
NCT03649061 · P. Verschueren
2018-06-08 – 2022-07-01 · Arthritis, Rheumatoid
What this study did
NCT02374021 · Brigham and Women's Hospital
2016-07 – 2021-05 · Arthritis, Rheumatoid
What this study did
NCT01602302 · Medical University of Graz
2012-06 – 2020-11-19 · Rheumatoid Arthritis
What this study did
NCT02878161 · Fen Li
2016-01 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT02433184 · University of Leeds
2011-07 – 2019-07 · Rheumatoid Arthritis
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT02109289 · Innovaderm Research Inc.
2014-04 – 2016-11 · Rheumatoid Arthritis, Vascular Inflammation
What this study did
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
NCT02346877 · Amgen
2015-04 – 2015-10 · Persistence to Enbrel
What this study did
NCT01927757 · Amgen
2013-05-06 – 2015-06-11 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT01783015 · Pfizer
2013-09 – 2014-08 · Rheumatoid Arthritis
What this study did
NCT02132234 · Jagiellonian University
2013-06 – 2014-07 · Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Hypertension
What this study did
NCT01875991 · Amgen
2013-06-05 – 2014-03-04 · Rheumatoid Arthritis, Plaque Psoriasis
What this study did
NCT00837434 · National Institute of Allergy and Infectious Diseases (NIAID)
2009-03 – 2014-01 · Rheumatoid Arthritis
What this study did
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did
NCT01313208 · Amgen
2011-03 – 2013-05 · Rheumatoid Arthritis
What this study did
Early phase / not applicable (19)
Psoriasis
NCT02258282 · Chengdu PLA General Hospital
2014-05 – 2022-12 · Psoriasis
What this study did
NCT00477191 · Massachusetts General Hospital
2007-05 – 2013-12 · Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
What this study did
NCT01170715 · Rockefeller University
2010-07-13 – 2013-09-09 · Psoriasis
What this study did
NCT01657513 · University Hospital, Gentofte, Copenhagen
2012-06 – 2013-07 · Psoriasis
What this study did
NCT00550030 · Medical University of Graz
2006-08 – 2010-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT00405275 · US Department of Veterans Affairs
2007-07 – 2012-05 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07184853 · First Affiliated Hospital of Zhejiang University
2025-09-25 – 2028-09-25 · Graft vs Host Disease
What this study did
NCT01610947 · University Hospital, Montpellier
2012-05-14 – 2018-10-18 · Spondyloarthritis
What this study did
NCT03033095 · University Hospital, Grenoble
2016-07 – 2018-03-28 · Spondylitis, Ankylosing
What this study did
NCT02722772 · First Affiliated Hospital of Harbin Medical University
2016-02 – 2017-08 · Osteoarthritis of Knee
What this study did
NCT02722811 · First Affiliated Hospital of Harbin Medical University
2016-02 – 2017-08 · Osteoarthritis Of Knee
What this study did
NCT02030613 · Assistance Publique - Hôpitaux de Paris
2013-10-01 – 2017-03-30 · Juvenile Idiopathic Arthritis
What this study did
NCT02031211 · Stanford University
2014-06 – 2016-10 · CRPS, Chronic Regional Pain Syndrome
What this study did
NCT00931957 · Tehran University of Medical Sciences
2010-10 – 2013-10 · Behcet Syndrome, Uveal Disease
What this study did
NCT00825344 · Johns Hopkins University
2009-01 – 2012-08 · Inguinal Hernia, Postoperative Pain
What this study did
NCT00413400 · Massachusetts General Hospital
2006-12 – 2009-09 · Metabolic Syndrome
What this study did
NCT00409318 · Massachusetts General Hospital
2004-04 – 2005-05 · Metabolic Syndrome
What this study did
NCT00276029 · University Hospitals, Leicester
2003-12 – 2004-09 · Asthma
What this study did
NCT00205231 · University of Wisconsin, Madison
2002-05 – 2004-05-01 · HIV Infections
What this study did
Used as active comparator (35)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (22)
Psoriasis
NCT03451851 · Janssen Research & Development, LLC
2018-07-11 – 2026-12-18 · Psoriasis
What this study did
NCT02471144 · Novartis Pharmaceuticals
2015-09-29 – 2023-03-30 · Chronic Severe Plaque-type Psoriasis
What this study did
NCT01646177 · Eli Lilly and Company
2012-07-28 – 2019-07-22 · Psoriasis
What this study did
NCT01597245 · Eli Lilly and Company
2012-05-18 – 2019-06-18 · Psoriasis
What this study did
NCT02346240 · UCB Biopharma S.P.R.L.
2015-02-11 – 2018-12-17 · Psoriasis, Plaque Psoriasis
What this study did
NCT01936688 · Sun Pharmaceutical Industries Limited
2013-09 – 2018-08 · Plaque-type Psoriasis
What this study did
NCT02134210 · Coherus Oncology, Inc.
2014-06-16 – 2016-05-12 · Plaque Psoriasis
What this study did
NCT01891864 · Sandoz
2013-06 – 2015-03 · Chronic Stable Plaque Psoriasis
What this study did
NCT01358578 · Novartis Pharmaceuticals
2011-06 – 2013-07 · Chronic Plaque Psoriasis
What this study did
NCT00710580 · AbbVie (prior sponsor, Abbott)
2008-07 – 2009-04 · Moderate to Severe Plaque Psoriasis
What this study did
NCT00691964 · AbbVie (prior sponsor, Abbott)
2008-05 – 2009-03 · Plaque Psoriasis
What this study did
NCT00454584 · Centocor, Inc.
2007-03 – 2009-01 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT06596772 · mAbxience Research S.L.
2024-10-03 – 2026-02-20 · Rheumatoid Arthritis (RA)
What this study did
NCT04079374 · Joint Stock Company "Farmak"
2018-09-03 – 2023-12-03 · Rheumatoid Arthritis
What this study did
NCT02308163 · Astellas Pharma Inc
2014-08-08 – 2017-11-22 · Rheumatoid Arthritis
What this study did
NCT02357069 · LG Life Sciences
2015-02 – 2016-12 · Arthritis, Rheumatoid
What this study did
NCT02115750 · Coherus Oncology, Inc.
2014-05 – 2016-05 · Rheumatoid Arthritis
What this study did
NCT01895309 · Samsung Bioepis Co., Ltd.
2013-06 – 2015-10 · Rheumatoid Arthritis
What this study did
NCT01394913 · EMS
2013-08 – 2014-06 · Rheumatoid Arthritis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02809781 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016-06 – 2018-12 · Spondylitis, Spondylitis, Ankylosing, Ankylosis, Arthritis, Spondylarthritis, Spondylarthropathies, Spinal Diseases, Musculoskeletal Diseases, Bone Diseases
What this study did
Phase 2 (2)
Rheumatoid Arthritis
NCT00713544 · AstraZeneca
2008-07 – 2009-04 · Rheumatoid Arthritis
What this study did
NCT00520572 · AstraZeneca
2007-08 – 2009-03 · Rheumatoid Arthritis
What this study did
Phase 1 (5)
Psoriasis
NCT01276847 · Merck Sharp & Dohme LLC
2011-03 – 2011-12 · Psoriasis
What this study did
Rheumatoid Arthritis
NCT02481180 · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2015-07-31 – 2017-11-06 · Rheumatoid Arthritis
What this study did
NCT01635686 · Daewoong Pharmaceutical Co. LTD.
2012-09 – 2013-06 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06392074 · mAbxience Research S.L.
2024-03-07 – 2025-05-12 · Healthy Volunteers
What this study did
NCT01431404 · Hanwha Chemical
2011-08 – 2013-06 · Healthy
What this study did
Phase 4 (5)
Psoriasis
NCT00936065 · Pfizer
2009-07 – 2011-04 · Moderate to Severe Psoriasis
What this study did
Rheumatoid Arthritis
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT02092467 · Pfizer
2014-03-14 – 2020-07-22 · Arthritis, Rheumatoid
What this study did
NCT01331837 · Hoffmann-La Roche
2011-08-02 – 2016-03-25 · Rheumatoid Arthritis
What this study did
NCT01021735 · University of Glasgow
2010-04 – 2015-04 · Rheumatoid Arthritis
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Psoriasis
NCT01001208 · Amgen
2009-11 – 2011-02 · Psoriasis
What this study did
Phase 1/2 (2)
Rheumatoid Arthritis
NCT03160001 · Faiq Gorial
2017-08-15 – 2018-12-10 · Rheumatoid Arthritis (RA)
What this study did
Other / comorbidity
NCT04082910 · Chinese PLA General Hospital
2019-09-15 – 2023-12-30 · Solid Tumor, Hematological Malignancy
What this study did
Phase 4 (1)
Psoriasis
NCT00832364 · Stiefel, a GSK Company
2009-10 – 2010-04 · Plaque Psoriasis
What this study did
Early phase / not applicable (1)
Psoriasis
NCT00800982 · University of California, San Francisco
2008-10 – 2012-03 · Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Etanercept (Enbrel): this drugApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Reliable signal
NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005)
NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001)
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3%
NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19%
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results).
NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results).
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002
NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphanot yet graded
NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants
NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Zymfentra)
Approved(overall)
Monoclonal antibodyTNF-alpha
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002.
NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results).
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Partial signalNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5)
NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8)
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Icotrokinra (Icotyde)Phase 3PeptideIL-23 receptornot yet gradedNo reviewed efficacy summary in this indication
JNJ-78934804
Phase 3(overall)
CombinationIL-23 p19, TNF-alpha
not yet graded(overall)
No reviewed efficacy summary in this indication
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo.
SonelokimabPhase 3Antibody-derived scaffoldIL-17A/FPartial signal
NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52).
NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled)
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
VunakizumabPhase 3Monoclonal antibodyIL-17Partial signal
NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively
ZasocitinibPhase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-10374Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
Hemay007
Phase 1(overall)
Small moleculeTNF-alpha
Partial signal(overall)
No reviewed efficacy summary in this indication
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication
SOR102
Phase 1(overall)
Biologic (subtype unspecified)TNF-alpha, IL-23 p19
Weak signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Enbrel (etanercept) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1Lung Transplant; ComplicationsEnrolling by invitation
Est. primary completion 2026-12 · NCT05950724 · CT.gov ↗
What to watch
Phase 2Tinnitus, Noise InducedActive not recruiting
Est. primary completion 2026-12 · NCT04066348 · CT.gov ↗
What to watch
2027 (3)
March 2027 (1)
Phase 4Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)Recruiting
Est. primary completion 2027-03-01 · NCT06707194 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableGraft vs Host DiseaseRecruiting
Est. primary completion 2027-09-25 · NCT07184853 · CT.gov ↗
What to watch
December 2027 (1)
Phase 1NeuroblastomaActive not recruiting
Est. primary completion 2027-12 · NCT03294954 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Alzheimer DiseaseRecruiting
Est. primary completion 2028-06 · NCT06585384 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3SAPHO SyndromeRecruiting
Est. primary completion 2028-10-18 · NCT06011889 · CT.gov ↗
What to watch
2029 (1)
November 2029 (1)
Phase 4Juvenile Idiopathic Arthritis (JIA)Not yet recruiting
Est. primary completion 2029-11-11 · NCT07904780 · CT.gov ↗
What to watch
2030 (1)
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch

See the full readout calendar ↗